Lucie Raskin: Comparing VTE Risk in Hormonal Contraceptives at NTHC 2026
Lucie Raskin, PhD student at University of Namur, shared on LinkedIn:
”Glad to have presented at NTHC 2026 (Namur Thrombosis and Hemostasis Center)!
I had the opportunity to share our work on a Network Meta-Analysis (NMA) assessing the risk of venous thromboembolism (VTE) associated with hormonal contraceptives (HCs).
This analysis allows us, within a single model, to compare the full range of HCs and to classify VTE risk according to the type of contraceptive.
By integrating all available evidence, this work provides a comprehensive overview that complements biological data and real-world pharmacovigilance findings.
Altogether, the evidence consistently suggests that natural estrogens may represent a safer option compared to EE-based COCs with respect to VTE risk.
I would like to thank my supervisors Jonathan Douxfils and Charlotte Beaudart, as well as the Research Unit in Clinical Pharmacology and Toxicology (URPC) team for their support.”
Stay updated with Hemostasis Today.
-
May 26, 2026, 13:21Isabelle Mahé: Frailty Does Not Mean Less Anticoagulation
-
May 26, 2026, 12:32Behçet Syndrome and Thrombosis: When Inflammation Becomes a Clot
-
May 26, 2026, 12:29Priya Prasad: When Blood Becomes the Battlefield – Transfusion Medicine Saves Lives
-
May 26, 2026, 12:21Mavis Agnes Kisakye: Uganda at the WFH Regional Conference on Blood Disorders
-
May 26, 2026, 12:19Megan Adediran: Giving Hope to People Living with Bleeding Disorders
-
May 26, 2026, 11:36Abid Ur Rahman: Understanding the Coagulation Cascade and Hemostasis
-
May 26, 2026, 11:35Isaac Okello: The Real Sickle Cell Crisis Is Not Only the Disease Itself
-
May 26, 2026, 11:34Ziad Omar: PTT and aPTT Testing – Reading the Intristic Pathway of Coagulation
-
May 26, 2026, 11:33Megan Griffiths: Advancing the Understanding of Risk and Outcomes in Pulmonary Hypertension